
Sign up to save your podcasts
Or


Harlan Krumholz, MD, FACC, JACC Editor-in-Chief, and Benjamin M. Scirica, MD, MPH, FACC, discuss the surprising benefits of semaglutide beyond weight loss and cardiovascular health from the SELECT trial, which investigated the effects of semaglutide on COVID-19 outcomes and non-cardiovascular deaths in patients with obesity and cardiovascular disease.
By American College of Cardiology4.2
162162 ratings
Harlan Krumholz, MD, FACC, JACC Editor-in-Chief, and Benjamin M. Scirica, MD, MPH, FACC, discuss the surprising benefits of semaglutide beyond weight loss and cardiovascular health from the SELECT trial, which investigated the effects of semaglutide on COVID-19 outcomes and non-cardiovascular deaths in patients with obesity and cardiovascular disease.

135 Listeners

320 Listeners

499 Listeners

886 Listeners

19 Listeners

32 Listeners

3,360 Listeners

139 Listeners

1,142 Listeners

62 Listeners

40 Listeners

198 Listeners

91 Listeners

368 Listeners

427 Listeners